Literature DB >> 14501583

5-lipoxygenase and atherosclerosis.

Margarete Mehrabian1, Hooman Allayee.   

Abstract

PURPOSE OF REVIEW: 5-Lipoxygenase (5LO) was recently identified as a gene that makes an important contribution to atherosclerosis in mice and humans, but the underlying mechanism(s) remains unknown. RECENT
FINDINGS: Studies of the 5LO pathway in other disease areas suggest that 5LO could contribute to atherosclerosis at different levels, such as lesion initiation, growth and cellular proliferation within the lesion, and/or destabilization of plaques that can lead to their rupture.
SUMMARY: Recent advances in our understanding of how 5LO is involved in the atherosclerotic process will have important implications for diagnostic and therapeutic strategies in the future.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501583     DOI: 10.1097/00041433-200310000-00005

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  29 in total

1.  Role of FLAP and PDE4D in myocardial infarction and stroke: target discovery and future treatment options.

Authors:  Hakon Hakonarson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

2.  Complex inheritance of the 5-lipoxygenase locus influencing atherosclerosis in mice.

Authors:  Anatole Ghazalpour; Xuping Wang; Aldons J Lusis; Margarete Mehrabian
Journal:  Genetics       Date:  2006-04-19       Impact factor: 4.562

3.  Intrapulmonary administration of leukotriene B(4) augments neutrophil accumulation and responses in the lung to Klebsiella infection in CXCL1 knockout mice.

Authors:  Sanjay Batra; Shanshan Cai; Gayathriy Balamayooran; Samithamby Jeyaseelan
Journal:  J Immunol       Date:  2012-02-29       Impact factor: 5.422

4.  5-lipoxygenase as an endogenous modulator of amyloid β formation in vivo.

Authors:  Jin Chu; Domenico Praticò
Journal:  Ann Neurol       Date:  2010-11-17       Impact factor: 10.422

5.  Association of PLA2G4A with myocardial infarction is modulated by dietary PUFAs.

Authors:  Jaana Hartiala; Elizabeth Gilliam; Susanna Vikman; Hannia Campos; Hooman Allayee
Journal:  Am J Clin Nutr       Date:  2012-02-29       Impact factor: 7.045

6.  Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells.

Authors:  Nambi Aiyar; Jyoti Disa; Zhaohui Ao; Haisong Ju; Sandhya Nerurkar; Robert N Willette; Colin H Macphee; Douglas G Johns; Stephen A Douglas
Journal:  Mol Cell Biochem       Date:  2006-08-08       Impact factor: 3.396

Review 7.  Polyunsaturated fatty acids and cardiovascular disease: implications for nutrigenetics.

Authors:  Hooman Allayee; Nitzan Roth; Howard N Hodis
Journal:  J Nutrigenet Nutrigenomics       Date:  2009-09-23

8.  Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.

Authors:  Lutz Fischer; Dieter Steinhilber; Oliver Werz
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

9.  Functional analysis of 5-lipoxygenase promoter repeat variants.

Authors:  Susanna Vikman; Romulo M Brena; Patrice Armstrong; Jaana Hartiala; Charles B Stephensen; Hooman Allayee
Journal:  Hum Mol Genet       Date:  2009-08-28       Impact factor: 6.150

10.  5-Lipoxygenase-mediated endogenous DNA damage.

Authors:  Wenying Jian; Seon Hwa Lee; Michelle V Williams; Ian A Blair
Journal:  J Biol Chem       Date:  2009-04-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.